This site is intended for Healthcare professionals only.

Urethritis-Urethral discharge in males-Standard Treatment Guidelines


Urethritis-Urethral discharge in males-Standard Treatment Guidelines

Introduction

Urethritis, manifested by urethral discharge, dysuria, or itching at the end of the urethra, is the response of the urethra to inflammation of any etiology. It is generally due to infection of the urethral mucosa with organisms (predominantly sexually transmitted, few cases nonsexually transmitted). Symptoms, if present, include discharge of mucopurulent or purulent material, dysuria, or urethral pruritus. Asymptomatic infections are also common.

Ministry of Health and Family Welfare, Government of India has issued the Standard Treatment Guidelines for Urethritis (Urethral discharge) in males.
Following are the major recommendations :

Case definition

The characteristic physical finding is urethral discharge, and the pathognomonic confirmatory laboratory finding is an increased number of polymorphonuclear leukocytes (PMNL) on Gram stain of a urethral smear or in the sediment of the first-voided urine.

Causative organisms: Urethritis can be

  • Gonococcal, or gonorrhea, when Neisseria gonorrhoeae is detected within the PMNL (may frequently be accompanied by chlamydial infections). Gonorrhoea is the second most commonly reported STI.
  • Nongonococcal if N. gonorrhoeae cannot be detected in the PMNL. The term nongonococcal urethritis (NGU) has many causes and in most cases no pathogen can be detected. These include.
    o Chlamydia trachomatis
    o Mycoplasma genitaliu
    o T. vaginalis
    o HSV
    o Adenovirus
    o Ureaplasma urealyticum
    o Enteric bacteria

NGU occurring soon after curative therapy for urethral gonorrhea is called Postgonococcal Urethritis (PGU).

INCIDENCE OF THE CONDITION IN OUR COUNTRY

Among the cases of urethritis presenting to STD clinics, the incidence of gonococcal urethritis is close to 65% and that of Non gonococcal Urethritis (NGU) is 35%. The common organisms causing NGU were chlamydia (28%) ureaplasma (11%) and mycoplasma (11%)[Ref 1].

DIFFERENTIAL DIAGNOSIS

Other causes of urethritis or urethral discharge which may not be sexually transmitted include.

  • Bacterial urethritis occurring in association with urinary tract infection, bacterial prostatitis, urethral stricture, phimosis, and secondary to catheterization or other instrumentation of the urethra.
  • Urethritis with congenital abnormalities, chemical irritation, and tumors.
  • Allergic etiology.
  • Stevens-Johnson syndrome may produce urethritis.

Complications

  • NGU among males infected with C. trachomatis include epididymitis and Reiter’s syndrome.
  • GU- The following complications may arise.

Complicated Gonococcal infection: Involves infection of urinary tract above the anterior urethra

  • posterior ureththritis, periurethral abscess
  • infection of Cowper’s/ Tyson’s glands
  • urethral stricture
  • prostatitis, epididymo-orchitis
  • corneal perforation, blindness
  • DGI (arthritis-dermatitis syndrome)

Disseminated Gonococcal Infection (DGI)

  • Petechial or pustular acral skin lesions, asymmetrical arthralgia, tenosynovitis, or septic arthritis.
  1. Complicated occasionally by perihepatitis and rarely by endocarditis or meningitis.
  2. Some strains of N. gonorrhoeae that cause DGI can cause minimal genital inflammation.

PREVENTION AND COUNSELING
General measures as applicable to all patients with suspected STIs

  • Educate and counsel patient and sex partner(s) regarding RTIs/STIs, genital cancers, safer sex practices and importance of taking complete treatment.
  • Treat partner(s) for the suspected organisms.
  • Advise sexual abstinence during the course of treatment to minimize transmission.
  • Promote the use of barrier contraception like condoms, educate about correct and consistent use.
  • Refer for voluntary counseling and testing for HIV, Syphilis and Hepatitis B.
  • Consider immunization against Hepatitis B.
  • Schedule return visit after 7 days to ensure treatment compliance as well as to see reports of tests done.
  • If symptoms persist, assess whether it is due to treatment failure or reinfection and advise prompt referral.

OPTIMAL DIAGNOSTIC CRITERIA, INVESTIGATIONS, TREATMENT & REFERRAL CRITERIA

Situation 1: At Secondary Hospital/ Non-Metro situation: Optimal Standards of Treatment in Situations where technology and resources are limited

Clinical Diagnosis
Based on clinical examination of the amount, character and color of discharge.

  • Urethral discharge should first be objectively documented.
  • If not visible on initial examination, an attempt should be made to strip or milk the urethra from proximal to distal to elicit the discharge.
  • If discharge still not detected, the patient should be examined the next morning, after not voiding overnight, to enhance the likelihood of reaching a firm diagnosis.

The color or character to be noted.

  • A yellowish color (most common) or greenish color (seen only occasionally) can be described as “purulent.”
  • A grey or white discharge often mixed with clear fluid should be labeled “mucoid” or “mixed.”
  • The third category is “clear.”

The presence or absence of meatitis, penile edema and enlarged inguinal lymph node should be determined.

Investigations

To validate the inflammatory nature of urethral discharge and to differentiate between GU and NGU.

  • Gram stain of urethral secretions demonstrating ≥5 WBC per oil immersion field.
  • Positive leukocyte esterase test on first-void urine.
  • Microscopic examination of first-void urine sediment demonstrating ≥10 WBC per high-power field.

Gram stain, preferred rapid diagnostic test for evaluating urethritis

  • Highly sensitive and specific in males
  • Nongonoccocal urethritis (NGU): microscopy indicates inflammation without GNID.
  • GU- High specificity (>99%) and sensitivity (>95%) for infection with N. gonorrhoeae in symptomatic men.

For complicated GU or DGI

  • Haematological and Biochemical tests (to rule out systemic involvement)
  • Echocardiography

Treatment

Standard Operating procedure
As dual infection is common and cannot be ruled out with reasonable certainty, the treatment for urethral discharge should adequately cover therapy for both, gonorrhea and chlamydial infections (Ref 5).

  • Treatment should be initiated as soon as possible after diagnosis.
  • Single-dose regimens advantageous: improve compliance, can be directly observed.
  • Treatment is mostly on an outpatient basis. Only cases with complicated gonococcal infections or disseminated gonococcal infections would require inpatient care.

Outpatient care

Recommended regimen for uncomplicated gonorrhea + chlamydia
Uncomplicated infections (disease limited to the anogenital region (anterior urethra or rectum).

– Tab. Cefixime 400 mg orally, single dose Plus

– Tab Azithromycin 1 gram orally single dose under supervision

  • Advise the patient to follow up after 7 days of start of therapy
  • To minimize transmission, abstain from sexual intercourse for 7 days after single-dose therapy or until completion of a 7-day regimen.
  • To minimize reinfection, abstain from sexual intercourse until all sex partners are treated.
  • All partners in the past 60 days before the initial diagnosis and any interim partners should be referred for evaluation and appropriate treatment.

Alternative drugs

  • Ceftriaxone (single injection of 250 mg)
  • Preferred in cases with oral sexual exposure (efficacy in treating pharyngeal infection)
  • As ofApril 2007, quinolones no longer recommended for the treatment of gonorrhea and associated conditions, such as PID (Ref 6).

Follow up
After seven days

– To see reports of tests done for HIV, syphilis and Hepatitis B

– If symptoms persist, to assess whether it is due to treatment failure or reinfection

– For prompt referral if required

– Test of cure is not recommended unless therapeutic noncompliance or reinfection is suspected.

When symptoms persist or recur after adequate treatment for gonorrhea and chlamydia
or
If discharge or only dysuria persists after 7 days

  • Reassess compliance and re-exposure: Retreatment with the initial regimen if not ensured.
  • Treatment completed but persistent symptoms and no objective signs of urethritis: only urinary alkalinisers, no extension of antimicrobial therapy.
  • Persistent urethritis (objectively assessed): treat with T. doxycycline (100 mg bd for 7 days)
  • Persistent urethritis (objectively assessed) after treatment with Doxycycline: might be caused by
    o doxycycline-resistant U. urealyticum or M. genitalium- treat with flouroquinolone (Ofloxacin) or macrolides (erythromycin).
    o T. vaginalis
    o Prostatic infection
  • Investigate these cases with culture or NAAT (PCR or TMA) on a urethral swab, first void urine or semen.
  • Recommended regime while awaiting the results.

Recommended Regimens

  • Metronidazole 2 g orally in a single dose
    OR
  • Tinidazole 2 g orally in a single dose
    PLUS
  • Azithromycin 1 g orally in a single dose (if not used for initial episode).
  • Index patient and partner(s), should be treated for Trichomonas vaginalis with Tab. Secnidazole 2gm orally, single dose (to treat for T. vaginalis).

Persistence of chronic prostatitis/chronic pelvic pain syndrome

  • Persistent pain (perineal, penile, or pelvic), discomfort, irritative voiding symptoms, pain during or after ejaculation, or new-onset premature ejaculation lasting for >3 months.
  • A four-glass test to localize pathogens to the prostate.
  • Referral to urologist should be considered. Providers should be alert to the possibility of in male patients experiencing.

Alternative treatments for NGU

  • Erythromycin base 500 mg orally four times a day for 7 days
    OR
  • Erythromycin ethylsuccinate 800 mg orally four times a day for 7 days
    OR
  • Levofloxacin 500 mg orally once daily for 7 days
    OR
  • Ofloxacin 300 mg orally twice a day for 7 days

Syndrome specific guidelines for partner management

  • Partner management recommended for all males regardless of any specific etiology as substantial number of female partners are affected.
  • All sex partners within the preceding 60 days should be referred for evaluation, testing, and empiric treatment
  • Treat female partners on same lines after ruling out pregnancy and history of allergies.

Management of pregnant partner

– Pregnant partners of male clients with urethral discharge should be examined by doing a per speculum as well as per vaginal examination

– Should be treated for gonococcal as well as chlamydial infections (Refer guidelines for cervicitis).

– Cephalosporins to cover gonococcal infection are safe and effective in pregnancy

– Recommended treatment regime.

  • Tab. Cefixime 400mg orally, single dose
    OR
  • Ceftriaxone 125mg by intramuscular injection
    PLUS
  • Tab. Erythromycin 500mg orally four times a day for seven days
    OR
  • Cap Amoxicillin 500mg orally, three times a day for seven days to cover chlamydial infection.

Special Considerations
HIV Infection

  • Urethritis might facilitate HIV transmission.
  • Same treatment regimen to be followed.

In Patient care
Required for

  • few cases of complicated gonococcal urethritis needing intravenous cephalosporins.
  • disseminated gonococcal infection.

Treatment
For complicated urethritis or Disseminated Gonococcal infection

  • Hospitalization is recommended for initial therapy of DGI, especially for patients who might not comply, in whom diagnosis is uncertain, for those who have purulent synovial effusions or other complications.
  • Examination for clinical evidence of endocarditis and meningitis should be performed.
  • Persons treated for DGI should be treated presumptively for concurrent C. trachomatis infection.

Complicated / Disseminated infection

  • Initialtherapy: (Step1)
    – Ceftriaxone 1 g IM or IV 24 hourly
    – Cefotaxime 1 g IV 8 hourly
  • Continue for seven days, may switch 24–48 hours after symptoms improve to (Step 2)
    – Cefixime 400mg twice daily.
  • Ophthalmia neonatorum
  • Ceftriaxone 25–50 mg/kg (1gm) IV orIM as a single dose
  • Cefotaxime 100mg/kg IM as a single dose
  • Frequent conjunctival irrigation with saline.
  • Regimen to be continued for 24–48 hours after improvement begins.
  • Switched to cefixime 400 mg orally twice daily to complete at least 1 week of antimicrobial therapy.

Management of Sex Partners

  • Partners are frequently asymptomatic
  • All partners to be treated as per urethritis guidelines

Gonococcal Meningitis and Endocarditis

Recommended Regimen
Ceftriaxone 1–2 g IV every 12 hours

Referral to a higher centre required for cultures, inpatient treatment and monitoring.

Referral criteria
Refer to higher centre

  • If the symptoms still persists after treatment step 1 and 2 and adequate partner treatment.

Situation 2: At Super Specialty Facility in Metro location where higher-end technology is available

Clinical Diagnosis
As in Situation 1

Investigations

  • Steps as being followed in Situation 1 above
  • In addition

Other tests depending on availability: (not widely available)

  • Culture for gonococcus and chlamydiae
  • Nucleic acid hybridization tests and NAATs for detection of genitourinary infection with N. gonorrhoeae.

Treatment
Same as above for uncomplicated infection of urethra.

Situation HUMAN RESOURCES INVESTIGATIONS DRUGS & CONSUMABLES EQUIPMENT
 

 

 

1

1 Dermatologist

1Microbiologist

1 Nurse

1 Technician

1 Counselor

Urethral smear for

Gram’s stain

First voided urine for

leukocyte esterase

First voided urine for

preparation of urinary

sediment, staining

and examination

Tab. Cefixime 400

mg orally, single

dose

Plus

Tab Azithromycin 1

gram orally single

dose under

supervision

Slides

Disposable

urethral swabs

Gloves

Staining material

Microscope

 

 

 

2

1 Dermatologist

1Microbiologist

1 Intensivist

1 Nurse

1 Technician

1 Counselor

As for situation 1

plus

Culture for

gonococcus and

chlamydiae (if

available)

Specific NAAT

As per situation 1

plus

Injectable

Ceftriaxone or

Cefotaxime

As per situation 1

plus

Paraphernalia for

intensive care

Guidelines by The Ministry of Health and Family Welfare :

Dr. M.K. Daga
Department of Medicine
Maulana Azad Medical College
New Delhi

The following two tabs change content below.
supriya kashyap

supriya kashyap

Supriya Kashyap Joined Medical Dialogue as Reporter in 2015 . she covers all the medical specialty news in different medical categories. She also covers the Medical guidelines, Medical Journals, rare medical surgeries as well as all the updates in medical filed. She is a graduate from Delhi University. She can be contacted at supriya.kashyap@medicaldialogues.in Contact no. 011-43720751
Source: self

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted